NishaLassiJacobsMD
Oncology • Coon Rapids, MNGastrointestinal Cancer, Hematologic Oncology
Attending physician Director of medical oncology at Mercy Hospital Site Medical Director for Minnesota Oncology—Coon Rapids
Dr. Jacobs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11850 Blackfoot St Ne
Suite 100
Coon Rapids, MN 55433Phone+1 763-712-2100Fax+1 763-712-2190
Summary
- I am a board certified medical oncologist, hematologist, and coagulation specialist. I completed my training at the Mayo Clinic and University of Minnesota. My specific interests include gastrointestinal malignancies, in particular colorectal cancer, pancreatic cancer, and hepatobiliary malignancies
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2009 - 2012
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2006 - 2009
University of Missouri Kansas City School of MedicineClass of 2006
Certifications & Licensure
MN State Medical License 2007 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 4 citationsPreemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.Aminah Jatoi, Fang-Shu Ou, Daniel H. Ahn, Tyler Zemla, Jennifer Le-Rademacher
The Oncologist. 2021-07-01 - 1 citationsA Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.Vered Stearns, Opeyemi A Jegede, Victor T-S Chang, Todd C Skaar, Jeffrey L Berenberg
Clinical Cancer Research. 2024-07-01 - 165 citationsRegorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.Tanios Bekaii-Saab, Fang-Shu Ou, Daniel H. Ahn, Patrick McKay Boland, Kristen K. Ciombor
The Lancet. Oncology. 2019-08-01
Books/Book Chapters
Professional Memberships
- Member
- Member
- Member
- Member
Other Languages
- Hindi, German, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
